Displaying 21 - 40 of 141
Statement of Commissioner Alvaro M. Bedoya Regarding the Commission's Policy Statement on Rebates and Fees in Exchange for Excluding Lower-Cost Drug Products
Date
By
Alvaro Bedoya, Commissioner
Matter Number
P221201
Concurring Statement of Commissioners Noah Joshua Phillips and Christine S. Wilson Regarding 6(b) Study of Pharmacy Benefit Managers
Date
By
Noah Joshua Phillips, Former Commissioner;
Christine S. Wilson, Former Commissioner
Matter Number
P221200
FTC Outlines Aggressive Approach to Policing Against Pandemic Predators in Testimony Before Senate Commerce Subcommittee
Date
The Federal Trade Commission testified before a Senate subcommittee today about the aggressive steps the agency is taking to police against pandemic predators who are capitalizing on the COVID-19...
FTC Comment to Food and Drug Administration Supports Agency’s Proposed Rule on Establishing Over-the-Counter Hearing Aids
Date
The Federal Trade Commission staff has submitted a comment to the Food and Drug Administration (FDA) in response to FDA’s request for comment on its proposed rule on establishing over-the-counter...
With Omicron Variant on the Rise, FTC Orders More Marketers to Stop Falsely Claiming Their Products Can Effectively Prevent or Treat COVID-19
Date
The Federal Trade Commission ordered more than 20 marketers nationwide to immediately stop making baseless claims that their products and supposed therapies can treat or prevent COVID-19. In cease-and...
FTC Issues Refunds Totaling More Than $1.8 Million to Consumers Defrauded by Lifewatch, Inc.’s Deceptive Medical Alert Telemarketing Scheme
Date
The Federal Trade Commission is sending 71,899 checks totaling more than $1.8 million to consumers, including many older Americans, tricked into paying for supposedly free in-home medical alert...
FTC Sends Refunds to Consumers Who Bought Deceptively Marketed Supplements to Treat Pain and Age-related Health Conditions
Date
The Federal Trade Commission is sending refund payments totaling more than $1.1 million to consumers who bought three supplements deceptively marketed as treatments for pain and other health...
Nordic Clinical, Inc. and Encore Plus Solutions, Inc.
In April 2020, the marketers of three supplements called Neurocet, Regenify, and Resetigen-D settled FTC charges that they deceptively promoted their products to older Americans using false claims that their products could stop pain and treat age-related ailments. The proposed order bars the defendants—five related companies and their principals from making any claims about the health benefits of their products unless they are true and supported by scientific evidence. In October 2021, the FTC announced it was returning $1.1 million to consumer who bought the defendants’ products.
Type of Action
Federal
Last Updated
FTC Matter/File Number
172 3132
172 3143
Case Status
Pending
FTC Sends Cease and Desist Demands to 10 Companies Suspected of Making Diabetes Treatment Claims without the Required Scientific Evidence
Date
The Federal Trade Commission sent cease-and-desist letters to 10 companies suspected of advertising unproven treatments or cures for diabetes, ordering the companies to stop making unsubstantiated...
FTC Approves Final Administrative Consent Order against Kushly Industries LLC and its Owner for Making Unsupported Health Claims for CBD Products
Date
Following a public comment period, the Federal Trade Commission has approved a final administrative consent order against Scottsdale, Arizona-based Kushly Industries LLC (Kushly) and the company’s...
FTC Sues PPE Marketer for Falsely Promising Quick Delivery of N95 Facemasks
Date
The Federal Trade Commission charged an online marketer with falsely promising consumers that he could quickly deliver facemasks and other personal protective equipment during the COVID-19 pandemic...
Promoter of $23,000 COVID-19 “Treatment” Plan Barred from Making Bogus Health Claims
Date
The medical director of California-based Golden Sunrise Nutraceutical, Inc., agreed to settle Federal Trade Commission charges that he took part in deceptively advertising a $23,000 treatment plan as...
FTC Approves Final Administrative Consent Orders against Companies that Deceptively Marketed Fish Oil Supplements with False Claims They Were Clinically Proven to Treat Liver Disease
Date
Following a public comment period, the Federal Trade Commission has approved final administrative consent orders against three companies, BASF SE , its subsidiary, BASF Corp. and DIEM Labs , which...
Federal Trade Commission, FDA Warn Five Companies That May Be Illegally Selling Dietary Supplements Claiming to Treat Infertility
Date
The Federal Trade Commission has joined the U.S. Food and Drug Administration (FDA) in sending warning letters to five companies that may be making false or unsubstantiated claims that their products...
Quickwork LLC and Eric A. Nepute
In April 2021, the FTC charged St. Louis-based chiropractor Eric Anthony Nepute and his company Quickwork LLC with violating the COVID-19 Consumer Protection Act and the Federal Trade Commission Act, by deceptively marketing products containing vitamin D and zinc as scientifically proven to treat or prevent COVID-19. This is the first such case in which the agency has sought civil penalties.
Type of Action
Federal
Last Updated
FTC Matter/File Number
202 3188
Case Status
Pending
The FTC Directed 30 More Marketers to Stop Making Unsupported Claims That Their Products and Therapies Can Effectively Prevent or Treat COVID-19
Date
The Federal Trade Commission announced that 30 more marketers nationwide have stopped making unsubstantiated claims that their products and therapies can prevent or treat COVID-19, the disease caused...
FTC Testifies before Congress on its Work to Curb COVID-19 Scams and Warn Consumers about Pandemic-related Frauds, Cons, and Swindles
Date
In testimony today before the Senate Commerce Committee’s Subcommittee on Consumer Protection, Product Safety, and Data Security, the Federal Trade Commission provided an update on its work to protect...
Federal Register Notice
BASF SE and DIEM Labs; Analysis of Proposed Consent Orders To Aid Public Comment
Date
Displaying 21 - 40 of 141